Active substances
Ipratropium + Salbutamol
- SFDA 1
- US FDA 13
- Health Canada 3
- US price lines 3
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| COMBIVENT UNIT DOSE VIAL NEBULISER SOLN. | 0.5 , 3.013 mg | inhalation solution · Inhalation use | 10 Single Dose Container | SAR 32.40 | NCE · Prescription | BOEHRINGER INGELHEIM | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE | EQ 0.083% BASE;0.017% | solution · inhalation | NEPHRON | Prescription | 31 Dec 2007 |
| ALBUTEROL SULFATE; IPRATROPIUM BROMIDE | 0.5MG; 0.017% | solution · inhalation | NEPHRON | Prescription | 31 Dec 2007 |
| ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE | EQ 0.083% BASE;0.017% | solution · inhalation | CIPLA | Prescription | 31 Dec 2007 |
| COMBIVENT RESPIMAT | EQ 0.1MG BASE/INH;0.02MG/INH | spray, metered · inhalation | BOEHRINGER INGELHEIM | Prescription | 7 Oct 2011 |
| ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE | EQ 0.083% BASE;0.017% | solution · inhalation | RITEDOSE CORP | Prescription | 1 Oct 2012 |
| ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE | EQ 0.083% BASE;0.017% | solution · inhalation | SUN PHARM | Prescription | 7 Aug 2017 |
| COMBIVENT | EQ 0.09MG BASE/INH;0.018MG/INH | aerosol, metered · inhalation | BOEHRINGER INGELHEIM | Discontinued | 24 Oct 1996 |
| DUONEB | EQ 0.083% BASE;0.017% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · inhalation | PHARMOBEDIENT | Discontinued | 21 Mar 2001 |
| ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE | EQ 0.083% BASE;0.017% | solution · inhalation | AIPING PHARM INC | Discontinued | 21 Dec 2006 |
| ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE | EQ 0.083% BASE;0.017% | solution · inhalation | TEVA PHARMS | Discontinued | 31 Dec 2007 |
| ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE | EQ 0.083% BASE;0.017% | solution · inhalation | WATSON LABS TEVA | Discontinued | 31 Dec 2007 |
| ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE | EQ 0.083% BASE;0.017% | solution · inhalation | APOTEX INC | Discontinued | 31 Dec 2007 |
| ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE | EQ 0.083% BASE;0.017% | solution · inhalation | LUOXIN AUROVITAS | Discontinued | 9 Jul 2020 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| COMBIVENT RESPIMAT | 02419106 | 100 MCG / ACT; 20 MCG / ACT | SOLUTION · INHALATION | BOEHRINGER INGELHEIM (CANADA) LTD LTEE |
| IPRATROPIUM BROMIDE AND SALBUTAMOL SULPHATE INHALATION SOLUTION | 02483394 | 0.5 MG / 2.5 ML; 2.5 MG / 2.5 ML | SOLUTION · INHALATION | JUNO PHARMA CANADA INC. |
| TEVA-COMBO STERINEBS | 02272695 | 0.5 MG / 2.5 ML; 2.5 MG / 2.5 ML | SOLUTION · INHALATION | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | COMBIVENT RESPIMAT 20-100 MCG | $124.15814 | per GM | 23 Sep 2026 |
| US NADAC | IPRATROPIUM-ALBUTEROL 0.5-3(2.5) MG/3 ML | $0.07869 | per ML | 23 Sep 2026 |
| US NADAC | IPRATROPIUM-ALBUTEROL 0.5-3(2.5) MG/3 ML | $0.08317 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Salbutamol 2.5mg/2.5ml / Ipratropium bromide 500micrograms/2.5ml nebuliser liquid unit dose vials | £24.10 | 60 unit dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.